https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-72008-02-13 00:00:002021-11-15 17:05:45Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-17 / Gene Ther. 2008 Mar;15(5):371-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-17 / Gene Ther. 2008 Mar;15(5):371-832008-01-17 00:00:002019-02-15 09:22:05Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-11-01 / Int. J. Oncol. 2007 Nov;31(5):1009-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-11-01 / Int. J. Oncol. 2007 Nov;31(5):1009-192007-11-01 00:00:002020-06-23 09:32:35Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-49
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-492007-10-04 00:00:002020-06-23 09:33:03Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-09-01 / Cancer Res. 2007 Sep;67(17):8285-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-09-01 / Cancer Res. 2007 Sep;67(17):8285-922007-09-01 00:00:002019-02-15 09:22:08Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-04-01 / Cancer Biother. Radiopharm. 2007 Apr;22(2):200-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-04-01 / Cancer Biother. Radiopharm. 2007 Apr;22(2):200-52007-04-01 00:00:002019-02-15 09:22:08In vitro induction of apoptosis in tumor cells by inactivated NDV and IAV
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-672007-03-01 00:00:002019-02-15 09:22:10Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):123-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):123-52007-03-01 00:00:002019-02-15 09:22:11Oncolytic virus therapy–foreword
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-15 / Cancer Res. 2007 Jan;67(2):429-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-15 / Cancer Res. 2007 Jan;67(2):429-322007-01-15 00:00:002019-02-15 09:22:11Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-10 / J. Virol. 2007 Mar;81(6):2817-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-10 / J. Virol. 2007 Mar;81(6):2817-302007-01-10 00:00:002019-02-15 09:00:16p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines
